A detailed history of Capital Performance Advisors LLP transactions in Humacyte, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 130 shares of HUMA stock, worth $700. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130
Holding current value
$700
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$5.11 - $9.46 $664 - $1,229
130 New
130 $0

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $555M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.